GenSight Biologics S.A. (SIGHT) EUR0.025
Gensight Biologics SA is a France-based company, which specializes in the clinical-stage biotechnology and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The Company, through I ts integrated development platform, combines a gene therapy-based approach with core technology platforms of mitochondrial targeting sequence and optogenetics. It focuses on development of therapies for severe retinal diseases with the goal of preserving or restoring vision in patients with sight-threatening ophthalmic diseases. The Company provides two development programs with products, such as GS010 which aims at treating rare mitochondrial genetic disease, and GS030 which technology makes cells responsive to light. The products are designed to be administered in a single treatment to each eye by intravitreal or subretinal injection.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.